Table 3 Persistence rates (PR) and persistence rate ratios (PRR) for HPV16/18 and HPV31/33/45 (vaccine and cross-protective types) over time, in years since vaccination

2

Unvaccinated

551

2

0.18 (0.05–0.73)

2

0.18 (0.05–0.73)

Ref

Vaccinated

626

0

0.00 (0.00–0.59)

1

0.08 (0.01–0.57)

0.44 (0.04–4.85)

3

Unvaccinated

513

2

0.19 (0.05–0.78)

2

0.19 (0.05–0.78)

Ref

Vaccinated

567

0

0.00 (0.00–0.65)

2

0.18 (0.04–0.71)

0.90 (0.13–6.42)

4

Unvaccinated

472

7

0.74 (0.35–1.56)

4

0.42 (0.16–1.13)

Ref

Vaccinated

515

0

0.00 (0.00–0.72)

3

0.29 (0.09–0.90)

0.69 (0.15–3.074)

5

Unvaccinated

455

10

1.10 (0.59–2.04)

3

0.33 (0.11–1.02)

Ref

Vaccinated

472

0

0.00 (0.00–0.78)

1

0.11 (0.01–0.75)

0.32 (0.03–3.09)

6

Unvaccinated

447

18

2.01 (1.27–3.20)

Ref

12

1.34 (0.76–2.36)

Ref

Vaccinated

438

1

0.11 (0.02–0.81)

0.06 (0.01–0.42)

2

0.23 (0.06–0.91)

0.17 (0.04–0.76)

7

Unvaccinated

433

11

1.27 (0.70–2.99)

Ref

5

0.58 (0.24–1.39)

Vaccinated

448

2

0.22 (0.06–0.89)

0.18 (0.04–0.79)

0

0.00 (0.00–0.82)

8

Unvaccinated

414

6

0.72 (0.33–1.61)

9

1.09 (0.57–2.09)

Ref

Vaccinated

429

0

0.00 (0.00–0.86)

5

0.58 (0.24–1.40)

0.54 (0.18–0.60)